|  |
| --- |
| **Clinical Trials Recruitment Fremantle Dermatology (Current trials)** |
| **Trial** | **Drug** | **Eligibility** | **Duration** | **Patients** | **Site open** | **comment** |
| **M23-696** | UpadacitinibIL4,13,31,22,2,6,7,15DupilumabIL4, 13 | * Chronic Atopic Dermatitis more than 3yrs,
* 12 -60yrs more than 40kgs
* Inadequate response to systemic
* **NO prior use of JAKs or Dupilumab**
* Greater than EASI 16 / vIGA3 BSA 10%
 | 32wks | At least 3 | yes | Closing soon |
| **M23-717-UP-AA** | UpadacitinibIL4,13,31,22,2,6,7,15 | * Alopecia Areata: hair loss more than 50%, current episode not exceeding 8yrs
* 12yrs - 64yrs greater than 30kgs
 | 160wks |  |  | Opening Oct Nov 23 |
| **17P-MC-DSAF** |  | * Phase 2b, double blind, placebo
* controlled study for Mod to severe Hidradenitis Suppurativa
* Failed 28 days of oral AB’s
 | 67wks |  |  | Opening Oct 23 |

**Current trials under recruitment or opening soon at Fremantle Dermatology includes brief outline of eligibility.**